covariates of age and education, evidenced a significant main effect, such that smokers (M = 1.10, SD = 0.07) worried about head and neck cancer significantly more than nonsmokers (M = 0.64, SD = 0.06), F (1,459) = 26.9.
Method:
The study cohort of 673 primary HNSCC comprised 391 CA and 282 AA. Risk variables included demographic, histopathology, and clinical/epidemiologic risk factors. Tumor DNA was interrogated for loss and gain of 113 genes with known involvement in HNSCC/cancer. Univariate analysis was followed by multivariate modeling with determination of c-index.
Results: Of the 39 univariate differences in race as AA and CA, multivariate modeling (c-index = 0.81) retained 6 variables (pCDKN2A) and aneupoidy of SCYA3 than CA tumors. AA were more likely to be unmarried, to have radiation treatment, and be more likely to be current and past smokers. Insurance type as HAP (Health Alliance Plan), Blue Cross, Medicaid, Medicare, and other was a significant determinant of race. AA were more likely to have Medicaid and Medicare. Insurance status by stage and radiation by stage were not significant.
Conclusion: Molecular modeling indicated significant differences between AA and CA for histopathology, patient factors, and tumor gene copy number alterations. Our data reiterate that for HNSCC, as in the case of other complex diseases, tumor genetics or biology is only one of many potential contributors to differences among racial groups.
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Dual Time Point Positron Emission Tomography imaging in the Head and Neck
Sanaz Harirchian, MD (presenter); Nasrin Chesani; Erik Cohen, MD Objective: Dual time point 18F-fluorodeoxyglucose-positron emission tomography (DTP-PET) is a new modality which may detect malignancy more accurately than standard PET/CT. Our main objective was to perform a pilot study to evaluate the characteristics of DTP-PET in primary head and neck squamous cell carcinomas (HNSCC) and lymph node metastases.
Method: A total of 36 patients with previously untreated HNSCC underwent preoperative PET/CT at 2 time points (mean 41-minute time difference) from 2007 to 2010. Mean and maximum standardized uptake values (SUV) were measured for the primary lesion and cervical lymph node metastases at both time points, and change in SUV over time was calculated.
Results: A total of 32 of 36 primary tumors (89%) had an increase in maximum SUV, between 13.93% and 264.65% (mean 43.7%) normalized to a 1-hour time difference. A total of 16 of 21 lymph node metastases (76%) had an increase in maximum SUV, between 13.49% and 284.15% (mean 57.1%). Change in mean SUV did not correlate as well with the presence of tumor.
Conclusion: This is the first description of DTP-PET in HNSCC. A total of 89% of primary tumors showed an increase in maximum SUV over time. These findings justify further study of DTP-PET as a method of detecting tumor in initial staging and after treatment.
Head and Neck Surgery
EGFR and iGF1R inhibition in Head and Neck Cutaneous Squamous Cell Carcinoma
Daniel R. Clayburgh, MD (presenter); Charlotte Proby; Melissa Wong; Neil D. Gross, MD Objective: 1) Determine if upregulation of insulin-like growth factor receptor (IGF1R) correlates with resistance to epidermal growth factor receptor (EGFR) inhibitors in patients with head and neck cutaneous squamous cell carcinoma (cSCCHN). 2) Evaluate the effect of combined inhibition of EGFR and IGF1R with tyrosine kinase inhibitors in cSCCHN.
Method: cSCC cell lines MET1, MET4, SCC12, and SCC13 were treated with the EGFR inhibitor erlotinib and/or the IGF1R inhibitor picropodophyllin, then evaluated for cell growth and expression of EGFR, IGF1R, and downstream signaling molecules. cSCCHN patient specimens were evaluated with antibodies for EGFR, IGF1R, phospho-Akt, and phospho-MAPK.
Results: Comparison of normal skin to cSCCHN specimens showed overexpression of EGFR (P = .0008) and IGF1R (P = .041). Treatment with erlotinib or picropodophyllin inhibited receptor phosphorylation (P < .01) and showed dose-dependent inhibition of cell growth in all cell lines. At intermediate concentrations, treatment with both inhibitors inhibited cell growth more effectively than either inhibitor alone (P < .05). Dual inhibition also decreased downstream activation of both Akt (P < .006) and p42/44 MAPK (P < .01). Specimens from a patient whose cSCCHN developed resistance to an EGFR inhibitor showed upregulation of IGF1R (P < .0001) and phosphorylated Akt (P < .01) compared to this same tumor prior to treatment with EGFR inhibitor.
Conclusion: Upregulation of IGF1R may be a pathway for resistance to EGFR inhibition in cSCCHN, possibly via increased
